Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

A new consortium of 27 partners coordinated by our researcher Prof Zameel Cader will tackle the challenge of discovery and characterisation of blood-brain barrier targets and transport mechanisms for brain delivery of therapeutics.

With this funding, we will be able to develop more sophisticated models that replicate the human blood-brain barrier far more accurately, allowing us to investigate how the barrier acts at a molecular level during disease.
- Associate Professor Zameel Cader

The blood-brain barrier is a protective layer between the brain’s blood capillaries and the cells that make up brain tissue. This barrier provides a defence against the pathogens and toxins that may be in our blood, allowing very few molecules to pass through. It can also prevent many drugs from passing across into the brain, and this presents a major problem in treating neurological conditions and metabolic diseases, especially when using antibody therapies. On the other hand, several neurological diseases could originate from a dysfunctional blood-brain barrier.

The funding from the Innovative Medicines Initiative (IMI) to the IM2PACT consortium will allow this public-private partnership, which includes leading international experts in the field, to facilitate the development of drugs to treat neurological disorders by: 

  • discovering and developing innovative and effective brain transport mechanisms
  • establishing and characterising blood-brain barrier models with good predictability in health and disease
  • identifying translational read-outs closer to the pathogenesis of neurodegeneration and mimicking altered blood-brain barrier under disease conditions
  • in-depth understanding of the biology of the blood-brain barrier and characterisation of various pathophysiological mechanisms across the blood-brain barrier.

IM2PACT will foster the development of disease-modifying treatment in a setting of personalised medicine. This partnership builds upon the research developed in the group of Prof Zameel Cader at the MRC Weatherall Institute of Molecular Medicine and Nuffield Department of Clinical Neurosciences, led by researcher Satyan Chintawar.

Dominique Lesuisse, Head of the Central Nervous System Barrier Group at Sanofi and IM2PACT project leader, said: 'Our existing models are not effective enough at telling us which drugs in particular biotherapeutics will break through the blood-brain barrier. IM2PACT will progress the state of the art and help devise optimal ways of getting therapies into the brain.'

With a budget of €18m, €9m of direct funding from IMI and €9m of in-kind funding from industry, IM2PACT is forming a large partnership to better understand the blood-brain barrier. The Innovative Medicines Initiative 2 Joint Undertaking is Europe’s biggest public private partnership and is funded jointly by the European Union´s Horizon 2020 research and innovation programme and the European pharmaceutical industry, represented by the European Federation of Pharmaceutical Industries and Associations (EFPIA).

Similar stories

Capturing immune cells that colonise the brain to prevent disease progression in multiple sclerosis

MRC WIMM researchers have revealed a population of immune cells that travel to the brain in patients with multiple sclerosis causing disease. They demonstrate how to trap these cells in the blood, meaning they can be targeted to prevent disease progression.

Angela Vincent honoured for excellence in epilepsy research

Emeritus Professor Angela Vincent received the Research Recognition Award, clinical science, at the annual meeting of the American Epilepsy Society.

European licence for migraine prevention drug

MRC WIMM research underpins the first treatment designed specifically for the prevention of migraines

World’s largest autism grant will transform research landscape

The largest research grant ever given for neurodevelopmental conditions has been awarded by the Innovative Medicines Initiative to an international consortium that includes the participation of Prof Zameel Cader.

Oxford Centre for Neuroinflammation launched

The new centre, located at the MRC WIMM, aims to shed light on the causes of neurodegenerative diseases and uncover new treatment pathways.

Prof David Beeson elected Fellow of the Academy of Medical Sciences

Many congratulations to Prof Beeson for this distinction recognising his exceptional contribution to the study of neuromuscular disorders.